Consolidated Balance Sheets - USD ($) $ in Millions,Consolidated Balance Sheets - USD ($) $ in Millions.1,"Dec. 31, 2016","Dec. 31, 2015"
Assets,,,
Cash and cash equivalents,[1][2], 2595, 3641
Short-term investments,[1],15255,19649
"Trade accounts receivable, less allowance for doubtful accounts: 2016—$609; 2015—$384",[1],8225,8176
Inventories,[1][3],6783,7513
Current tax assets,[1],3041,2662
Other current assets,[1],2249,2154
Assets held for sale,[1],801,9
Total current assets,[1],38949,43804
Long-term investments,[1],7116,15999
"Property, plant and equipment, less accumulated depreciation",[1][4][5],13318,13766
"Identifiable intangible assets, less accumulated amortization",[1],52648,40356
Goodwill,[1],54449,48242
Noncurrent deferred tax assets and other noncurrent tax assets,[1],1812,1794
Other noncurrent assets,[1],3323,3420
Total assets,[1],171615,167381
Liabilities and Equity,,,
"Short-term borrowings, including current portion of long-term debt: 2016—$4,225; 2015—$3,719",[1][6],10688,10159
Trade accounts payable,[1],4536,3620
Dividends payable,[1],1944,1852
Income taxes payable,[1],437,418
Accrued compensation and related items,[1],2487,2359
Other current liabilities,[1],11023,10990
Total current liabilities,[1],31115,29399
Long-term debt,[1][7],31398,28740
"Pension benefit obligations, net",[1],6406,6310
"Postretirement benefit obligations, net",[1],1766,1809
Noncurrent deferred tax liabilities,[1],30753,26877
Other taxes payable,[1],4000,3992
Other noncurrent liabilities,[1],6337,5257
Total liabilities,[1],111776,102384
Commitments and Contingencies,[1],,
"Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2016—597; 2015—649",[1],24,26
"Common stock, $0.05 par value; 12,000 shares authorized; issued: 2016—9,230; 2015—9,178",[1],461,459
Additional paid-in capital,[1],82685,81016
"Treasury stock, shares at cost: 2016—3,160; 2015—3,003",[1],-84364,-79252
Retained earnings,[1],71774,71993
Accumulated other comprehensive loss,[1],-11036,-9522
Total Pfizer Inc. shareholders’ equity,[1],59544,64720
Equity attributable to noncontrolling interests,[1],296,278
Total equity,[1][8],59840,64998
Total liabilities and equity,[1], 171615, 167381
,,,
"[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] The change from December 31, 2015 reflects, among other things, the reclassification of $377 million to Assets held for sale (see Note 2B). [4] Reflects legacy Medivation and legacy Anacor amounts in 2016, commencing on the Medivation acquisition date, September 28, 2016, and Anacor acquisition date, June 24, 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date, September 3, 2015. [5] The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $457 million to Assets held for sale (see Note 2B) and, to a lesser extent, impairments and the impact of foreign exchange, partially offset by capital additions. [6] The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2016 or December 31, 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments. [7] The fair value of our long-term debt (not including the current portion of long-term debt) was $34.9 billion as of December 31, 2016 and $32.7 billion as of December 31, 2015. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. [8] Amounts may not add due to rounding.",[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] The change from December 31 2015 reflects among other things the reclassification of 377 million to Assets held for sale -see Note 2B. [4] Reflects legacy Medivation and legacy Anacor amounts in 2016 commencing on the Medivation acquisition date September 28 2016 and Anacor acquisition date June 24 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date September 3 2015. [5] The decrease in total property plant and equipment is primarily due to depreciation the reclassification of 457 million to Assets held for sale -see Note 2B and to a lesser extent impairments and the impact of foreign exchange partially offset by capital additions. [6] The differences between the estimated fair values and carrying values of held-to-maturity debt securities private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31 2016 or December 31 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of 547 million as of December 31 2015 which are used as hedging instruments. [7] The fair value of our long-term debt -not including the current portion of long-term debt was 34.9 billion as of December 31 2016 and 32.7 billion as of December 31 2015. The fair value measurements for our long-term debt are based on Level 2 inputs using a market approach. [8] Amounts may not add due to rounding.,[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] The change from December 31 2015 reflects among other things the reclassification of 377 million to Assets held for sale -see Note 2B. [4] Reflects legacy Medivation and legacy Anacor amounts in 2016 commencing on the Medivation acquisition date September 28 2016 and Anacor acquisition date June 24 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date September 3 2015. [5] The decrease in total property plant and equipment is primarily due to depreciation the reclassification of 457 million to Assets held for sale -see Note 2B and to a lesser extent impairments and the impact of foreign exchange partially offset by capital additions. [6] The differences between the estimated fair values and carrying values of held-to-maturity debt securities private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31 2016 or December 31 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of 547 million as of December 31 2015 which are used as hedging instruments. [7] The fair value of our long-term debt -not including the current portion of long-term debt was 34.9 billion as of December 31 2016 and 32.7 billion as of December 31 2015. The fair value measurements for our long-term debt are based on Level 2 inputs using a market approach. [8] Amounts may not add due to rounding.,[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] The change from December 31 2015 reflects among other things the reclassification of 377 million to Assets held for sale -see Note 2B. [4] Reflects legacy Medivation and legacy Anacor amounts in 2016 commencing on the Medivation acquisition date September 28 2016 and Anacor acquisition date June 24 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date September 3 2015. [5] The decrease in total property plant and equipment is primarily due to depreciation the reclassification of 457 million to Assets held for sale -see Note 2B and to a lesser extent impairments and the impact of foreign exchange partially offset by capital additions. [6] The differences between the estimated fair values and carrying values of held-to-maturity debt securities private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31 2016 or December 31 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of 547 million as of December 31 2015 which are used as hedging instruments. [7] The fair value of our long-term debt -not including the current portion of long-term debt was 34.9 billion as of December 31 2016 and 32.7 billion as of December 31 2015. The fair value measurements for our long-term debt are based on Level 2 inputs using a market approach. [8] Amounts may not add due to rounding.
